JP2015515487A - 抗ｐｄｇｆ−ｃ抗体 - Google Patents

抗ｐｄｇｆ−ｃ抗体 Download PDF

Info

Publication number
JP2015515487A
JP2015515487A JP2015507520A JP2015507520A JP2015515487A JP 2015515487 A JP2015515487 A JP 2015515487A JP 2015507520 A JP2015507520 A JP 2015507520A JP 2015507520 A JP2015507520 A JP 2015507520A JP 2015515487 A JP2015515487 A JP 2015515487A
Authority
JP
Japan
Prior art keywords
antibody
seq
pdgf
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015507520A
Other languages
English (en)
Japanese (ja)
Inventor
フロモン，クラウディア
ゴー，ホア，チュー
ツヴァール，リチャード
ノートバート，ソフィー
Original Assignee
スロンボジェニックス エヌ．ブイ．
スロンボジェニックス エヌ．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スロンボジェニックス エヌ．ブイ．, スロンボジェニックス エヌ．ブイ． filed Critical スロンボジェニックス エヌ．ブイ．
Publication of JP2015515487A publication Critical patent/JP2015515487A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015507520A 2012-04-24 2013-04-24 抗ｐｄｇｆ−ｃ抗体 Pending JP2015515487A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261637372P 2012-04-24 2012-04-24
US61/637,372 2012-04-24
EP12165314.1 2012-04-24
EP12165314 2012-04-24
US201261727231P 2012-11-16 2012-11-16
EP12192943.4 2012-11-16
EP12192943 2012-11-16
US61/727,231 2012-11-16
PCT/EP2013/058513 WO2013160359A1 (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Publications (1)

Publication Number Publication Date
JP2015515487A true JP2015515487A (ja) 2015-05-28

Family

ID=49482233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015507520A Pending JP2015515487A (ja) 2012-04-24 2013-04-24 抗ｐｄｇｆ−ｃ抗体

Country Status (13)

Country Link
US (1) US9884910B2 (enExample)
EP (1) EP2841454A1 (enExample)
JP (1) JP2015515487A (enExample)
KR (1) KR20150005631A (enExample)
CN (1) CN104321343A (enExample)
AU (1) AU2013254690B2 (enExample)
BR (1) BR112014025560A2 (enExample)
CA (1) CA2871528A1 (enExample)
IN (1) IN2014DN09717A (enExample)
MX (1) MX2014012843A (enExample)
NZ (2) NZ700274A (enExample)
RU (1) RU2014140116A (enExample)
WO (1) WO2013160359A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501957A (ja) * 2015-11-10 2019-01-24 パラクリン セラピューティクス エービー Ｐｄｇｆ−ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置
JP2019527545A (ja) * 2016-07-01 2019-10-03 パラクライン セラピューティクス アーベー Ｐｄｇｆ−ｃｃの阻害のための方法および組成物
JP2021505554A (ja) * 2017-12-04 2021-02-18 ラボラトリオス・サルバト・ソシエダッド・アノニマＬａｂｏｒａｔｏｒｉｏｓ Ｓａｌｖａｔ， Ｓ．Ａ． 眼の後部の疾患を治療するためのドベシル酸を含む眼科用局所組成物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013254690B2 (en) 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies
US11390661B2 (en) 2016-06-27 2022-07-19 Aicuris Anti-Infective Cures Gmbh HCMV entry inhibitors
KR101943083B1 (ko) 2017-03-30 2019-01-29 (주)케어젠 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도
KR101943081B1 (ko) 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
KR102726837B1 (ko) * 2021-09-29 2024-11-07 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도
US20250051435A1 (en) * 2023-08-11 2025-02-13 Invetx, Inc. Anti-il-5 antibodies and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08511940A (ja) * 1993-06-25 1996-12-17 アメリカ合衆国 αＰＤＧＦ受容体に対するモノクローナル抗体およびその使用
JP2002531127A (ja) * 1998-12-07 2002-09-24 ザイモジェネティクス，インコーポレイティド 成長因子相同体ｚｖｅｇｆ３
JP2006528663A (ja) * 2003-07-25 2006-12-21 ザイモジェネティクス，インコーポレイティド 肝細胞癌を治療する方法
JP2010500872A (ja) * 2006-08-03 2010-01-14 アストラゼネカ アクチボラグ Ｐｄｇｆｒ−アルファに対して指向性のターゲテッド結合剤およびその使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991019515A1 (en) 1990-06-21 1991-12-26 The Board Of Trustees Of The Leland Stanford Junior University Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
EP1064382B1 (en) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
CA2344561A1 (en) 1998-09-30 2000-04-06 Ludwig Institute For Cancer Research Platelet-derived growth factor c, dna coding therefor, and uses thereof
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
AU8031700A (en) 1999-10-21 2001-04-30 Zymogenetics Inc. Method of treating fibrosis
JP2003533675A (ja) * 2000-03-28 2003-11-11 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 血小板由来成長因子ｃ（ｐｄｇｆ−ｃ）を発現する非ヒトトランスジェニック動物およびそれらの使用
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20050282233A1 (en) 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
US8147828B2 (en) * 2006-04-17 2012-04-03 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
AU2013254690B2 (en) 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08511940A (ja) * 1993-06-25 1996-12-17 アメリカ合衆国 αＰＤＧＦ受容体に対するモノクローナル抗体およびその使用
JP2002531127A (ja) * 1998-12-07 2002-09-24 ザイモジェネティクス，インコーポレイティド 成長因子相同体ｚｖｅｇｆ３
JP2006528663A (ja) * 2003-07-25 2006-12-21 ザイモジェネティクス，インコーポレイティド 肝細胞癌を治療する方法
JP2010500872A (ja) * 2006-08-03 2010-01-14 アストラゼネカ アクチボラグ Ｐｄｇｆｒ−アルファに対して指向性のターゲテッド結合剤およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE BIOTECHNOLOGY, 2005, VOL.23, NO.9, P.1105-1116, JPN6017002493, ISSN: 0003487662 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501957A (ja) * 2015-11-10 2019-01-24 パラクリン セラピューティクス エービー Ｐｄｇｆ−ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置
JP7048505B2 (ja) 2015-11-10 2022-04-05 パラクリン セラピューティクス エービー Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置
JP2022058781A (ja) * 2015-11-10 2022-04-12 パラクリン セラピューティクス エービー Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置
JP2019527545A (ja) * 2016-07-01 2019-10-03 パラクライン セラピューティクス アーベー Ｐｄｇｆ−ｃｃの阻害のための方法および組成物
JP2022130488A (ja) * 2016-07-01 2022-09-06 パラクライン セラピューティクス アーベー Ｐｄｇｆ－ｃｃの阻害のための方法および組成物
JP7437000B2 (ja) 2016-07-01 2024-02-22 パラクライン セラピューティクス アーベー Ｐｄｇｆ－ｃｃの阻害のための方法および組成物
JP2021505554A (ja) * 2017-12-04 2021-02-18 ラボラトリオス・サルバト・ソシエダッド・アノニマＬａｂｏｒａｔｏｒｉｏｓ Ｓａｌｖａｔ， Ｓ．Ａ． 眼の後部の疾患を治療するためのドベシル酸を含む眼科用局所組成物
JP7846501B2 (ja) 2017-12-04 2026-04-15 ラボラトリオス・サルバト・ソシエダッド・アノニマ 眼の後部の疾患を治療するためのドベシル酸を含む眼科用局所組成物

Also Published As

Publication number Publication date
CA2871528A1 (en) 2013-10-31
WO2013160359A1 (en) 2013-10-31
US20150232546A1 (en) 2015-08-20
CN104321343A (zh) 2015-01-28
IN2014DN09717A (enExample) 2015-07-31
KR20150005631A (ko) 2015-01-14
US9884910B2 (en) 2018-02-06
RU2014140116A (ru) 2016-06-10
MX2014012843A (es) 2017-01-23
EP2841454A1 (en) 2015-03-04
NZ724395A (en) 2018-03-23
AU2013254690B2 (en) 2017-12-07
BR112014025560A2 (pt) 2017-07-04
NZ700274A (en) 2016-10-28
AU2013254690A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
US12037392B2 (en) Treatment regimens using anti-NKG2A antibodies
AU2018346447B2 (en) Restoration of T cell activity via the CD39/CD73 axis
CN111363041B (zh) 新型抗-pd-l1抗体
RU2571224C2 (ru) Гуманизированные антитела против axl
KR102453227B1 (ko) 항-axl 길항성 항체
US9884910B2 (en) Anti-PDGF-C antibodies
CN114181310B (zh) 抗tigit抗体、其药物组合物及用途
CA3227972A1 (en) Anti-pvrig/anti-tigit bispecific antibodies and applications thereof
EP3825330A1 (en) Anti-cd117 antibodies and methods of use thereof
KR20240038043A (ko) 약학적 조성물 및 용도
KR20230132544A (ko) 신규한 항-그렘린1 항체
WO2022240833A1 (en) Alpha 5 beta 1 integrin binding agents and uses thereof
JP2021501583A (ja) 抗体および使用方法
JP2024542914A (ja) ヒトｃｘｃｌ１６抗体およびその使用
TWI888704B (zh) 抗ｃｄ７３之抗體及其應用
JP2025516434A (ja) 抗ｃｄ７３抗体およびその使用
RU2776121C2 (ru) Новые анти-pd-l1 антитела
HK40089230A (en) Pharmaceutical composition and use
HK40032298A (en) Novel anti-pd-l1 antibodies
HK40032298B (en) Novel anti-pd-l1 antibodies
WO2013139956A1 (en) Antibodies abrogating cell binding to lactadherin
HK1260737B (en) Novel anti-pd-l1 antibodies
HK1260737A1 (en) Novel anti-pd-l1 antibodies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180424